{"disease":{"id":"systemic-vasculitis","name":"systemic vasculitis"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05879419","title":"Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2005,"lead_sponsor_name":"University of Sao Paulo General Hospital","has_results":false},{"nct_id":"NCT02466217","title":"Phenomics in Autoimmune and Inflammatory Diseases","phase":"","overall_status":"COMPLETED","enrollment_count":537,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT07188285","title":"Mass Spectrometry-based Immune Profiling in Autoimmune Diseases","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":500,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT03410290","title":"Journey of Patients With Vasculitis From First Symptom to Diagnosis","phase":"","overall_status":"COMPLETED","enrollment_count":456,"lead_sponsor_name":"University of Pennsylvania","has_results":false},{"nct_id":"NCT06593041","title":"ROLE of PLATELETS in the PATHOPHYSIOLOGY of SYSTEMIC LUPUS","phase":"","overall_status":"RECRUITING","enrollment_count":450,"lead_sponsor_name":"University Hospital, Strasbourg, France","has_results":false},{"nct_id":"NCT03762824","title":"Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":300,"lead_sponsor_name":"Region Skane","has_results":false},{"nct_id":"NCT06462768","title":"Neutrophil Extracellular Traps in Different Forms of Systemic Sclerosis","phase":"","overall_status":"RECRUITING","enrollment_count":260,"lead_sponsor_name":"CHU de Reims","has_results":false},{"nct_id":"NCT06763783","title":"Vaccination Against Herpes Zoster in Patients With Inflammatory Rheumatic Diseases","phase":"PHASE4","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":240,"lead_sponsor_name":"Region Skane","has_results":false},{"nct_id":"NCT07251179","title":"Characterization of Autoreactive b Lymphocytes in Autoimmune Diseases and Immune Deficiencies","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":200,"lead_sponsor_name":"University Hospital, Strasbourg, France","has_results":false},{"nct_id":"NCT03543527","title":"Study of Refractory and/or Relapsing TAkayasu aRTeritis","phase":"","overall_status":"UNKNOWN","enrollment_count":150,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT03941184","title":"Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity","phase":"","overall_status":"COMPLETED","enrollment_count":114,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT07278609","title":"The RheumSafer Study: Improving Medication Appropriateness in People With Rheumatic Conditions","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"McGill University Health Centre/Research Institute of the McGill University Health Centre","has_results":false},{"nct_id":"NCT06350110","title":"Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":75,"lead_sponsor_name":"Essen Biotech","has_results":false},{"nct_id":"NCT07246096","title":"Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Changhai Hospital","has_results":false},{"nct_id":"NCT07037732","title":"Circulating B-cell, Drug and Anti-drug Antibodies Monitoring in Patients Treated With Rituximab for Autoimmune Disorders","phase":"","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Centre Hospitalier Universitaire de Nice","has_results":false},{"nct_id":"NCT06794008","title":"BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT03937856","title":"Smartphone Mindfulness Meditation for Patients With Rheumatic Diseases","phase":"NA","overall_status":"TERMINATED","enrollment_count":49,"lead_sponsor_name":"Johns Hopkins University","has_results":false},{"nct_id":"NCT07339540","title":"the Safety and Efficacy of Targeted BCMA In Vivo LV Injection for Recurrent or Refractory Autoimmune Diseases","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":45,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT07212322","title":"A Study of CD19 UCAR-T Cells in Subjects With Autoimmune Diseases","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":24,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT06056921","title":"Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":24,"lead_sponsor_name":"Chongqing Precision Biotech Co., Ltd","has_results":false},{"nct_id":"NCT05115370","title":"Vaccination Perception in Inflammatory Conditions - Flu, Pneumonia and COVID-19","phase":"","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"University of Nottingham","has_results":false},{"nct_id":"NCT06548607","title":"Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Nanjing Bioheng Biotech Co., Ltd.","has_results":false},{"nct_id":"NCT06775912","title":"Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":18,"lead_sponsor_name":"Nanjing Bioheng Biotech Co., Ltd.","has_results":false},{"nct_id":"NCT07236801","title":"Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":18,"lead_sponsor_name":"China Immunotech (Beijing) Biotechnology Co., Ltd.","has_results":false},{"nct_id":"NCT07104721","title":"A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":18,"lead_sponsor_name":"China Immunotech (Beijing) Biotechnology Co., Ltd.","has_results":false},{"nct_id":"NCT07123519","title":"A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":18,"lead_sponsor_name":"China Immunotech (Beijing) Biotechnology Co., Ltd.","has_results":false},{"nct_id":"NCT07236762","title":"An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":18,"lead_sponsor_name":"China Immunotech (Beijing) Biotechnology Co., Ltd.","has_results":false},{"nct_id":"NCT07526350","title":"MTS109 in Patients With Refractory Autoimmune Diseases","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":15,"lead_sponsor_name":"Shanghai Changzheng Hospital","has_results":false},{"nct_id":"NCT06614270","title":"Anti-CD19 IL-10/IL15 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases","phase":"NA","overall_status":"RECRUITING","enrollment_count":15,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT05859997","title":"Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":15,"lead_sponsor_name":"Bioray Laboratories","has_results":false},{"nct_id":"NCT02556866","title":"Rituximab Plus Corticosteroids in Non-infectious Active Mixed Cryoglobulinemia Vasculitis","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":14,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT07413341","title":"A Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune Diseases","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":12,"lead_sponsor_name":"Therorna","has_results":false},{"nct_id":"NCT06978647","title":"A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":12,"lead_sponsor_name":"China Immunotech (Beijing) Biotechnology Co., Ltd.","has_results":false},{"nct_id":"NCT07315087","title":"CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":12,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT06941129","title":"CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":12,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT06549296","title":"Clinical Study on Targeted CD19CAR-T Therapy for Autoimmune Diseases","phase":"EARLY_PHASE1","overall_status":"SUSPENDED","enrollment_count":12,"lead_sponsor_name":"Nanjing Bioheng Biotech Co., Ltd.","has_results":false},{"nct_id":"NCT07301164","title":"Clinical Study of BCT301 Cell Injection Therapy for Refractory Autoimmune Diseases","phase":"EARLY_PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":10,"lead_sponsor_name":"Peking University Third Hospital","has_results":false},{"nct_id":"NCT07490275","title":"Allogeneic CD19/BCMA-Targeted CAR-γδT Cell Therapy: Safety and Preliminary Pharmacodynamics in Relapsed/Refractory Autoimmune Diseases","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":9,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT06821659","title":"Safety and Efficacy of Universal CAR-T Cells (UWD-CD19) Combined with Immunosuppressants in the Treatment of Refractory Autoimmune Diseases","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":9,"lead_sponsor_name":"Peking University Third Hospital","has_results":false},{"nct_id":"NCT06420154","title":"The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refractory Autoimmune Diseases","phase":"EARLY_PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":9,"lead_sponsor_name":"First Affiliated Hospital of Wenzhou Medical University","has_results":false},{"nct_id":"NCT06828042","title":"Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":9,"lead_sponsor_name":"Peking University Third Hospital","has_results":false},{"nct_id":"NCT06379646","title":"An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease","phase":"NA","overall_status":"RECRUITING","enrollment_count":6,"lead_sponsor_name":"China Immunotech (Beijing) Biotechnology Co., Ltd.","has_results":false},{"nct_id":"NCT06373081","title":"Anti-CD19-CD3E-CAR-T Cells in Relapsed/Refractory Autoimmune Disease","phase":"NA","overall_status":"RECRUITING","enrollment_count":6,"lead_sponsor_name":"Shanghai Changzheng Hospital","has_results":false},{"nct_id":"NCT06462144","title":"IMPT-514 in Systemic Lupus Erythematosus, Anca-associated Vasculitis, and Idiopathic Inflammatory Myopathy","phase":"EARLY_PHASE1","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","has_results":false}],"total":44},"guidelines":[],"source":"Drug Landscape verified database"}